MENU
Showcases Stock ranks Forex

Kazia Therapeutics Ltd ADR (KZIA)
1.8  -0.06 (-3.23%) 08-08 16:00
Open: 1.82 Pre. Close: 1.86
High: 1.93 Low: 1.71
Volume: 857,583 Market Cap: 25M
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 1.932 - 1.943 1.943 - 1.953
Low: 1.687 - 1.698 1.698 - 1.708
Close: 1.784 - 1.802 1.802 - 1.818
Stock Technical Analysis
Overall:     
Target: Six months: 4.16
One year: 5.55
Support: Support1: 1.63
Support2: 1.36
Resistance: Resistance1: 3.56
Resistance2: 4.75
Pivot: 2.90
Moving Averages: MA(5): 1.81
MA(20): 3.12
MA(100): 5.50
MA(250): 7.63
MACD: MACD(12,26): -0.69
Signal(12,26,9): -0.55
%K %D: %K(14,3): 7.83
%D(3): 7.49
RSI: RSI(14): 19.73
52-Week: High: 12.28
Low: 1.63
Change(%): -80.8
Average Vol(K): 3-Month: 868
10-Days: 1582
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ KZIA ] has closed above bottom band by 18.8%. Bollinger Bands are 119.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
Stock chart
Stock News
Mon, 08 Aug 2022
Early Trading Has Kazia (KZIA) on the Move for August 8 - Equities News

Mon, 08 Aug 2022
Kazia Therapeutics (KZIA): Ambiguity in GBM But Pipeline Still Busy - AccessWire

Mon, 01 Aug 2022
Healthcare Stocks Moving Monday: OTRK, AEMD, TXMD, GOVX, KZIA, BGXX, IMAB, TRHC - InvestorsObserver

Wed, 06 Jul 2022
Sector Update: Health Care Stocks Catch Fire in Afternoon Trade - InvestorsObserver

Thu, 30 Jun 2022
Proactive news headlines including Buru Energy, Hawsons Iron, Red River Resources and ioneer Ltd - GlobeNewswire

Wed, 31 Dec 1969


Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 13.20
Shares Float (M) 9.79
% Held by Insiders
% Held by Institutions 2.71
Shares Short (K) 145
Shares Short Prior Month (K) 36
Stock Financials
EPS -0.520
Book Value (p.s.) 2.870
Profit Margin -99.27
Operating Margin -86.96
Return on Assets (ttm) -19.6
Return on Equity (ttm) -52.8
Qtrly Rev. Growth 754.7
Gross Profit (p.s.) 1.150
Sales Per Share 1.151
EBITDA (p.s.) -0.872
Qtrly Earnings Growth
Operating Cash Flow (M) -8.23
Levered Free Cash Flow (M) -1.02
Stock Valuation
PE Ratio -3.46
PEG Ratio
Price to Book value 0.63
Price to Sales 1.56
Price to Cash Flow -2.89
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android